

Marseille, France, September 18, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the *European Society of Medical Oncology Virtual Congress 2020*,

HalioDx partners will present 2 clinical studies conducted in expert centers worldwide, including Immune Checkpoint Inhibitors, in various solid tumors, during the Science weekend (Sept. 17 and 21, 2020). Jérôme Galon in an oral presentation, will offer an update on Colorectal tumour immunology during the Education weekend (Oct. 17, 2020).

Investigating Immunoscore® and additional proprietary immune-based assays in a broad number of clinical studies and cancer indications is the core of HalioDx strategy for establishing its assays as prognostic indicators and predictive factors for response to drugs, and contribute to precision medicine in the era of immuno-oncology and combination therapies. A recent achievement of this approach is the inclusion of Immunoscore® in the 2020 ESMO Clinical Practice Guidelines for its ability to refine the prognosis of early colon cancer patients, in conjunction with the TNM

[\[1\]](#)

scoring and thus to adjust the chemotherapy decision-making process in stage II and in low-risk stage III patients.

“We are pleased that recently ESMO recognized the extensive clinical validation of Immunoscore® in localised Colon cancer. That will facilitate access to Immunoscore® testing for patients. Beyond that, there is still a lot of indications and therapeutic strategies in which HalioDx can bring to patients and oncologists valuable information to guide cancer care and contribute to precision medicine.

Being under the spotlights at main congresses like ESMO 2020 is key for a company innovating in immuno-oncology diagnostics,”

said Vincent Fert, CEO of HalioDx.

Agenda

- Intermediate results (analysis of the first 100 pts) of the PIONeeR biomarker study,ÂÂ Precision Immuno-Oncology for advanced Precision Immuno-Oncology for advanced Non-small-cell lung carcinoma (NSCLC) patients treated with PD(L)1 immune checkpoint inhibitors *F. Barlesi et al.* Session Proffered Paper - NSCLC metastatic 2 on Sept 21, 2020 at 14:49, Room Channel 3 (

[link – for attendees only](#)

)

- Intermediate results of the Phase II NICOLE study evaluating anti PD-1 nivolumab in unselected MMR early stage Colon Cancer (CC). *A. Avallone et al.* EPoster session, Sept 17, 2020 (

[link – for](#)

[attendees only](#)

)

- Colorectal tumour immunology: Update, Jérôme Galon Special symposium – Session: Immunotherapy in colorectal cancer: Present and future Oct. 17, 2020 - 14:30 (

[link – for attendees only](#)

)

[\[1\]](#) Tumour, Node, Metastasis.